NovAliX has announced that it has entered into a multi-year drug research collaboration in the field of trisomy 21 with the Fondation Jérôme Lejeune.
NovAliX will use its expertise and capabilities in medicinal chemistry and structural biology to develop small molecule lead candidates targeting the cystathionine-beta-synthase (CBS).
Indeed inhibition of CBS over-expression has been associated with restoration of cognitive impairment in animal models afflicted with trisomy.
"We look forward to progressing our research programs for treating trisomy 21 leveraging NovAliX expertise in structure-based drug design and capabilities in advanced lead generation methodologies" said Dr Henri Bléhaut, Chief Scientific Officer at the Fondation Jérôme Lejeune.
Stephan Jenn, President of NovAliX, said "we are very pleased to investigate a novel research approach for the Down syndrome (trisomy 21) and to support the Fondation Jérôme Lejeune in its efforts to improve patients conditions".